Minute Insight: NeuroOne Amends Deal With Zimmer Biomet To Shore Up Balance Sheet
Executive Summary
Zimmer Biomet agreed to amend its exclusive development and distribution agreement with NeuroOne to pay $3.5m for 350,000 of stock. The deal will help NeuroOne continue to develop its Evo stereoelectroencephalography brain-mapping electrodes without further diluting the company’s stock.
You may also be interested in...
NeuroOne: Thinner Is Better When It Comes To Brain Electrodes
NeuroOne manufactures the thinnest FDA-approved stereoelectroencephalography electrode for 30-day use, and a recent Emory University study could further expand their applications.
Acclarent Expects TruDi Shaver Blade To Prevent Repeat ENT Surgeries
The FDA recently cleared the TruDi Shaver Blade, an electromagnetically navigated blade for the incision and removal of soft and hard tissue or bone in ear, nose, throat, and maxillofacial surgery, as well as head and neck and skull-base surgery.
Inflation, Supply Chain Headaches And Staffing Shortages: CEOs Talk About 'Big Picture' Challenges
Although procedure volumes have mostly recovered from the shock of COVID-19 two years ago, the effects of the pandemic on the medtech sector and the economy overall will be felt for years to come. In recent analyst and sales and earnings presentations, CEOs of major medtech companies faced questions about how their company is handling these major "macro" issues.